Sponsor Overview
Explore verified public information about Biosolution Co.,Ltd's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 0 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
No evidence found.
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria CartiLife is an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects. Suitable for treatment of defects which are: ICRS grade III or IV, with defect sizes between 2 ~ 10 cm^2. Available Therapies via Single-Patient EA Biosolution Co.,Ltd does not provide access to investigational products outside of clinical trials. We encourage patients to participate in clinical trials of our investigational therapies whenever possible, because clinical trials are designed, conducted, and monitored to ensure that the safety and efficacy are appropriately evaluated before they are submitted to regulatory agencies for review with the intent to make them more broadly available to patients.
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.